Relay Therapeutics
RLAY
125 hedge funds and large institutions have $3.26B invested in Relay Therapeutics in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 62 increasing their positions, 22 reducing their positions, and 23 closing their positions.
182% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 22
10% more capital invested
Capital invested by funds: $2.96B → $3.26B (+$302M)
3.48% more ownership
Funds ownership: 95.12% → 98.6% (+3.5%)
9% less funds holding
Funds holding: 137 → 125 (-12)
38% less funds holding in top 10
Funds holding in top 10: 13 → 8 (-5)
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$149M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$34.9M |
| 3 |
BlackRock
New York
|
+$24.4M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$23.4M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$52.2M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$39M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$34.6M |
| 4 |
Goldman Sachs
New York
|
-$25.4M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$21.8M |
RLAY Hedge Fund Activity: Q2 2021 in Review
125 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q2 2021, worth a combined $3.26B — up 10% from $2.96B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of RLAY and 11 opened new positions — a net loss of 12 holders — while 22 trimmed existing stakes and 62 added.
The largest buyer was Fidelity Investments, adding an estimated $149M. The largest seller was Foresite Capital Management IV, cutting an estimated $52.2M.
- 125 institutional investors held Relay Therapeutics (RLAY) as of Q2 2021, down from 137 in Q1 2021.
- Funds reported $3.26B of Relay Therapeutics stock for Q2 2021, up 10% quarter-over-quarter.
- 11 funds opened new Relay Therapeutics positions in Q2 2021 and 23 closed out, a net change of -12 holders.
- The largest Relay Therapeutics buyer in Q2 2021 was Fidelity Investments, an estimated $149M added.
- The largest Relay Therapeutics seller in Q2 2021 was Foresite Capital Management IV, an estimated $52.2M sold.
Based on aggregated 13F filings for Q2 2021.